POINT BIOPHARMA GLOBAL INC(NASDAQ:PNT) stock Fundamental Analysis

Fundamental Rating

PNT gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. PNT has an excellent financial health rating, but there are some minor concerns on its profitability. PNT has a correct valuation and a medium growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PNT was profitable.

In the past year PNT had a positive cash flow from operations.

1.2 Ratios

With an excellent Return On Assets value of 20.22%, PNT belongs to the best of the industry, outperforming 99.49% of the companies in the same industry.

PNT's Return On Equity of 22.77% is amongst the best of the industry. PNT outperforms 97.81% of its industry peers.

Looking at the Return On Invested Capital, with a value of 18.63%, PNT belongs to the top of the industry, outperforming 99.33% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	20.22%
ROE	22.77%
ROIC	18.63%

ROA(3y)-20.26%

ROA(5y)N/A

ROE(3y)-32.35%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 39.62%, PNT belongs to the best of the industry, outperforming 99.33% of the companies in the same industry.

Looking at the Operating Margin, with a value of 44.22%, PNT belongs to the top of the industry, outperforming 98.99% of the companies in the same industry.

		Industry Rank	Sector Rank
OM	44.22%
PM (TTM)	39.62%
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PNT is creating some value.

PNT has more shares outstanding than it did 1 year ago.

There is no outstanding debt for PNT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

PNT has an Altman-Z score of 16.90. This indicates that PNT is financially healthy and has little risk of bankruptcy at the moment.

PNT has a better Altman-Z score (16.90) than 91.23% of its industry peers.

PNT has a debt to FCF ratio of 0.06. This is a very positive value and a sign of high solvency as it would only need 0.06 years to pay back of all of its debts.

PNT has a better Debt to FCF ratio (0.06) than 97.30% of its industry peers.

PNT has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.

PNT has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: PNT outperforms 43.17% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	0.06
Altman-Z	16.9

ROIC/WACC1.67

WACC11.15%

2.3 Liquidity

PNT has a Current Ratio of 9.13. This indicates that PNT is financially healthy and has no problem in meeting its short term obligations.

PNT has a Current ratio of 9.13. This is in the better half of the industry: PNT outperforms 73.52% of its industry peers.

PNT has a Quick Ratio of 9.13. This indicates that PNT is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of PNT (9.13) is better than 73.69% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	9.13
Quick Ratio	9.13

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 195.40% over the past year.

EPS 1Y (TTM)195.4%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%11.54%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

PNT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.94% yearly.

Based on estimates for the next years, PNT will show a very strong growth in Revenue. The Revenue will grow by 72.58% on average per year.

EPS Next Y9.21%

EPS Next 2Y-2.62%

EPS Next 3Y36.93%

EPS Next 5Y22.94%

Revenue Next Year-14.35%

Revenue Next 2Y21.4%

Revenue Next 3Y112.36%

Revenue Next 5Y72.58%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 15.06 indicates a correct valuation of PNT.

97.47% of the companies in the same industry are more expensive than PNT, based on the Price/Earnings ratio.

PNT is valuated rather cheaply when we compare the Price/Earnings ratio to 29.62, which is the current average of the S&P500 Index.

PNT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	15.06
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PNT indicates a rather cheap valuation: PNT is cheaper than 97.98% of the companies listed in the same industry.

Compared to the rest of the industry, the Price/Free Cash Flow ratio of PNT indicates a rather cheap valuation: PNT is cheaper than 97.64% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	14.37
EV/EBITDA	6.16

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

PNT's earnings are expected to grow with 36.93% in the coming years. This may justify a more expensive valuation.

PEG (NY)1.64

PEG (5Y)N/A

EPS Next 2Y-2.62%

EPS Next 3Y36.93%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PNT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

POINT BIOPHARMA GLOBAL INC

NASDAQ:PNT (12/26/2023, 8:10:43 PM)

After market: 12.51 +0.01 (+0.08%)

12.5

+0.02 (+0.16%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-13 2023-11-13/bmo

Earnings (Next)03-22 2024-03-22/amc

Inst Owners0.74%

Inst Owner Change0%

Ins Owners5.11%

Ins Owner Change0%

Market Cap1.33B

Analysts69.33

Price Target15.05 (20.4%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)21.81%

Min EPS beat(2)19.08%

Max EPS beat(2)24.55%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)2

Avg Revenue beat(2)312.79%

Min Revenue beat(2)211.88%

Max Revenue beat(2)413.69%

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)2.12%

EPS NQ rev (1m)0%

EPS NQ rev (3m)14.94%

EPS NY rev (1m)0%

EPS NY rev (3m)12.19%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)83.86%

Revenue NY rev (1m)0%

Revenue NY rev (3m)25.31%

Valuation

		Industry Rank	Sector Rank
PE	15.06
Fwd PE	N/A
P/S	5.46
P/FCF	14.37
P/OCF	11.89
P/B	3.14
P/tB	3.14
EV/EBITDA	6.16

EPS(TTM)0.83

EY6.64%

EPS(NY)-1.04

Fwd EYN/A

FCF(TTM)0.87

FCFY6.96%

OCF(TTM)1.05

OCFY8.41%

SpS2.29

BVpS3.98

TBVpS3.98

PEG (NY)1.64

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	20.22%
ROE	22.77%
ROCE	24.56%
ROIC	18.63%
ROICexc	81.93%
ROICexgc	81.93%
OM	44.22%
PM (TTM)	39.62%
GM	N/A
FCFM	38.02%

ROA(3y)-20.26%

ROA(5y)N/A

ROE(3y)-32.35%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.51

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	0.06
Debt/EBITDA	0.04
Cap/Depr	742.31%
Cap/Sales	7.92%
Interest Coverage	250
Cash Conversion	101.45%
Profit Quality	95.96%
Current Ratio	9.13
Quick Ratio	9.13
Altman-Z	16.9

F-Score6

WACC11.15%

ROIC/WACC1.67

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)195.4%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%11.54%

EPS Next Y9.21%

EPS Next 2Y-2.62%

EPS Next 3Y36.93%

EPS Next 5Y22.94%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year-14.35%

Revenue Next 2Y21.4%

Revenue Next 3Y112.36%

Revenue Next 5Y72.58%

EBIT growth 1Y234.92%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-34.05%

EBIT Next 3Y38.92%

EBIT Next 5Y-10.32%

FCF growth 1Y261.67%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y371.58%

OCF growth 3YN/A

OCF growth 5YN/A

POINT BIOPHARMA GLOBAL INC (PNT) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens